Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Oxaliplatin is a platinum-based chemotherapy drug that primarily targets DNA, causing crosslinks and inhibiting replication. While it doesn't directly bind to tubulin or inhibit microtubule polymerization like classical microtubule-targeting agents (e.g., taxanes, vinca alkaloids), it can indirectly affect microtubule function by disrupting cellular processes such as nucleolar stress and impacting the expression/localization of proteins involved in mitotic spindle formation. This indirect effect contributes to its antitumor activity, particularly in colorectal cancer.
Indirect inhibition of microtubule function through DNA crosslinking and disruption of cellular processes required for proper spindle assembly during mitosis.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Microtubule Function (Indirect Inhibition via Oxaliplatin).